Massachusetts-based drug developer Sarepta Therapeutics has acquired private biotech Myonexus Therapeutics for $165m, after the publication of promising early data on a gene therapy clinical trial. The deal is expected to close in mid-2017, and will be funded by an undisclosed amount from investors including venture capital firm Andreessen Horowitz. Early results from three patients demonstrated MYO-101 prompted an average increase of 51% in beta-sarcoglycan, a protein needed for muscle function, which LGMD sufferers lack.
Massachusetts-based drug developer Sarepta Therapeutics has acquired private biotech Myonexus Therapeutics for $165m, after the publication of promising early data on a gene therapy clinical trial. Myonexus is testing the use of MYO-101 in patients with beta-sarcoglycanopathy, a severe form of limb-girdle muscular dystrophy (LGMD). Early results from three patients demonstrated MYO-101 prompted an average increase of 51% in beta-sarcoglycan, a protein needed for muscle function, which LGMD sufferers lack.